title: Subretinal fluid in uveitic macular edema: effect on vision and response to therapy.
abstract: OBJECTIVE
  To evaluate the effect of subretinal fluid (SRF), imaged with spectral-domain optical coherence tomography (SD-OCT), on visual acuity outcomes in cases of uveitic macular edema (ME), and to analyze the response of SRF and uveitic ME to therapy.
  
  
  METHODS
  Retrospective case series.
  
  
  METHODS
  One hundred and one eyes of 75 patients with uveitic ME, as imaged by SD-OCT, were identified at a single tertiary-care referral center. The main outcome measures were best-corrected visual acuity, central subfield thickness (CSFT), and rates of macular edema improvement (≥20% reduction in CSFT), and resolution (defined as reduction of CSFT to <315 μm) of ME at 3 and 6 months follow-up.
  
  
  RESULTS
  Forty eyes of 29 patients had SRF on SD-OCT at presentation, which was associated with greater macular thickness (mean CSFT 488 μm vs 362 μm, P = .0001) and worse visual acuity than ME without SRF (20/115 vs 20/51, P = .015). However, eyes with SRF responded more favorably to treatment, and at 3 and 6 months of follow-up they achieved greater rates of improvement and resolution of ME than eyes without SRF (77% improved and 50% resolved at 6 months, vs 20% and 13%, respectively; P = .003 and P = .017, respectively) and recovered to a similar level of visual acuity (20/62 vs 20/42 at 6 months, P = .54).
  
  
  CONCLUSIONS
  SRF in uveitic ME is associated with thicker retinas and worse visual acuity on presentation but responds more favorably to treatment and displays greater rates of edema resolution and visual acuity improvement.
authors.affiliation: Department of Ophthalmology, The Mount Sinai School of Medicine, New York, New York, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Lehpamer
authors.forename: Erin
authors.initials: E
authors.lastname: Moshier
authors.forename: Naomi
authors.initials: N
authors.lastname: Goldberg
authors.forename: Jessica
authors.initials: J
authors.lastname: Ackert
authors.forename: James
authors.initials: J
authors.lastname: Godbold
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Jabs
mesh_terms: D005122:Exudates and Transudates; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008269:Macular Edema / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D012160:Retina / Q000473:pathology*; D012189:Retrospective Studies; D058471:Subretinal Fluid / Q000502:physiology*; D041623:Tomography, Optical Coherence; D014605:Uveitis / Q000188:drug therapy / Q000503:physiopathology*; D014786:Vision Disorders / Q000503:physiopathology; D014792:Visual Acuity / Q000502:physiology*
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents